{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-035922","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2026-08-04T11:05:28+00:00","discovered_at":"2026-08-04T11:10:03.447898+00:00","generated_at":"2026-08-04T11:10:24.495727+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Elite Pharmaceuticals launches generic Requip XL; addresses $10M U.S. market","bullets":["Launched generic Ropinirole Extended-Release Tablets (2, 4, 6, 8, 12 mg) for Parkinson's disease.","Product marketed under Elite Laboratories label; branded Requip XL and equivalents had $10M U.S. sales (IQVIA, 12 months ending June 2026).","Expands Elite's niche generic portfolio; company operates cGMP/DEA-registered facility in Northvale, NJ."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-035922","json":"https://secwatch.observer/filing/0001493152-26-035922.json","markdown":"https://secwatch.observer/filing/0001493152-26-035922.md","text":"https://secwatch.observer/filing/0001493152-26-035922.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226035922/0001493152-26-035922-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226035922/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T11:10:24.495727+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}